For the quarter ending 2025-09-30, IOVA made $67,455K in revenue. -$91,253K in net income. Net profit margin of -135.28%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total net revenue | 67,455 | 59,952 | 49,324 | 37,205 |
| Cost of sales | 38,477 | 56,664 | 49,741 | 26,402 |
| Research and development | 75,174 | 79,363 | 76,879 | 76,004 |
| Selling, general, and administrative | 34,555 | 37,699 | 43,925 | 36,948 |
| Depreciation and amortization | 9,007 | - | - | - |
| Restructuring charges | 5,143 | - | - | - |
| Total costs and expenses | 162,356 | 173,726 | 170,545 | 139,354 |
| Loss from operations | -94,901 | -113,774 | -121,221 | -102,149 |
| Interest and other income, net | 1,243 | 4,104 | 3,220 | 6,457 |
| Net loss before income taxes | -93,658 | -109,670 | -118,001 | -95,692 |
| Income tax (expense) benefit | -2,405 | 1,988 | -1,838 | 75 |
| Net loss | -91,253 | -111,658 | -116,163 | -95,767 |
| Earnings per share, diluted | - | -0.33 | -0.36 | -0.33 |
| Weighted average number of shares outstanding, diluted | - | 334,511 | 322,868 | -149,104.5 |
| Earnings per share, basic | -0.25 | -0.33 | -0.36 | -0.33 |
| Weighted average number of shares outstanding, basic | 364,037 | 334,511 | 322,868 | -149,104.5 |
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)